Saturday 17 October 2026
Morning Edition
ZOTPAPER

News without the noise

ZOTPAPER
US Politics

RFK Jr. pushes FDA to ease access to unproven peptide drugs despite staff safety concerns

Proposed 'Interim Access Policy' would give enforcement discretion to specialty pharmacies, drawing concern from agency scientists

By LineZotpaper
Published
Read Time1 min
The Food and Drug Administration under Health Secretary Robert F. Kennedy Jr. is advancing a policy to allow easier access to unproven peptide drugs popular in Kennedy's Make America Healthy Again movement, despite internal staff findings that the drugs lack sufficient safety and efficacy data and may cause harm.

The FDA has submitted an "Interim Access Policy" on peptides for White House review through the Office of Management and Budget, according to a filing notice posted on an OMB website. While the posting does not detail the proposal, sources familiar with the plan told the Associated Press that it would grant the FDA "enforcement discretion" on certain peptide drugs. This approach would allow the agency to decline to enforce current restrictions on peptides, providing reassurance to specialty pharmacies that want to begin manufacturing them without fear of regulatory action.

The Department of Health and Human Services, which oversees the FDA, did not respond to a request for comment. FDA staff scientists have reportedly concluded that the drugs have not been sufficiently studied to establish safety and effectiveness, and that they may pose risks to patients.

§

Analysis

Why This Matters

  • The policy could weaken the FDA's traditional gatekeeping role, allowing untested drugs into the market without rigorous clinical trials.
  • Peptide drugs are often marketed as anti-aging or performance-enhancing treatments, and their unregulated use could expose patients to unknown side effects.
  • The move sets a precedent for future administrations to bypass scientific review for politically favored therapies.

Background

The FDA is responsible for ensuring that drugs sold in the United States are safe and effective. Peptides are short chains of amino acids that can act as signaling molecules in the body; while some have approved medical uses, many are sold as unregulated supplements or compounded products. The "Make America Healthy Again" movement associated with RFK Jr. has promoted alternative treatments and questioned mainstream medical oversight.

Key Perspectives

MAHA movement supporters: They argue that patients should have greater freedom to access experimental peptides, particularly for conditions where conventional treatments are limited. FDA staff scientists: They caution that the drugs have not been adequately tested for safety or efficacy and that making them widely available could lead to patient harm. Critics and public health advocates: They warn that enforcement discretion undermines the FDA's scientific standards and could open the door to a wave of unapproved products.

What to Watch

  • The outcome of the White House OMB review and whether the policy is made public.
  • Congressional reaction, particularly from committees overseeing health and FDA funding.
  • Potential lawsuits from patient safety groups or industry competitors challenging the policy.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe